🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the register
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
2026-525244-14-00Metastatic prostate cancer
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
15/09/2026
Phase IV
Attachment Development and Learning in ADHD: The Role of Dopamine.
2025-525122-35-00Attention-Deficit/Hyperactivity Disorder (ADHD)
UZ Leuven
Mental Disorders
Belgium
15/09/2026
Phase II
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
2026-526207-30-00End stage kindey disease
Aplagon Oy
Not possible to specify
Sweden, Spain, Finland
15/09/2026
Phase II
Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00Acute lymphoblastic leukaemia
Fundacion PETHEMA
Neoplasms
Spain
15/09/2026
Phase II
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00Pulmonary Disease, Chronic Obstructive
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany
15/09/2026
Phase IV
Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
2025-524829-40-00Severe unipolar depression treated with electroconvulsive t…
Varsinais-Suomen hyvinvointialue
Mental Disorders
Finland
15/09/2026
Phase IV
REconsidering Long-TErm ASpirin in the Elderly in Secondary Prevention of Coronary Artery Disease (RELEASE) Norway: A Randomised, Registry-based Trial
2026-526941-91-00Chronic coronary syndrome
Vestre Viken HF
Circulatory and Respiratory Physiological Phenomena
Norway
15/09/2026
Phase I
Detection of rEPO using Dried Blood Spot (DBS)
2026-526613-29-01healthy participants
Consorci Mar Parc De Salut De Barcelona
Not possible to specify
Spain
15/09/2026
Phase II
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
2025-524655-30-00Parkinson’s disease
H. Lundbeck A/S
Nervous System Diseases
Czechia, Spain, Italy, Germany, Sweden
15/09/2026
Phase II
Optimization of De-EscalatiON strategies in early breast cancer
2026-527524-27-00breast cancer
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Neoplasms
Italy
14/09/2026
Phase I
Study of the distribution of linezolid in the prostate in patients who underwent endoscopic prostate enucleation – DiProLine
2026-527015-42-00A Study of the Distribution of Linezolid in the Prostate in…
Centre Hospitalier Le Mans
Male Urogenital Diseases
France
14/09/2026
Phase I
Comparative bioavailability study of Colistin Cyclops® administered as 3 different doses
2025-524657-14-00No therapeutic indication in the current bioavailability tr…
CCDRD Cooperative Clinical Drug Research and Development AG, PureIMS B.V.
Respiratory Tract Diseases
Bulgaria
14/09/2026
Phase III
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…
Grifols Therapeutics LLC
Immune System Diseases
Italy, Poland, Czechia, France, Spain
14/09/2026
Phase I/II
A study assessing the safety, tolerability, pharmacokinetics and efficacy of single and multiple doses of NNC0638-0355 in participants with overweight or obesity
2026-526797-16-00Obesity and overweight
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands
14/09/2026
Phase I
A Study to Evaluate the Safety, Tolerability, and Activity of a Novel Oral Anticancer Drug (FLC‑436) in Patients With Refractory or Relapsed Solid Malignancies
2026-526215-10-00Refractory or Relapsed Solid Malignancies
Fileclo Sp. z o.o.
Neoplasms
Poland
14/09/2026
Phase I
A study to evaluate how well linaprazan glurate is absorbed and how it controls stomach acid (Part I) and investigation of the influence of a meal on the blood levels of linaprazan glurate (Part II) in healthy volunteers
2026-527465-30-00Healthy volunteer
Cinclus Pharma Holding AB (publ)
Bacterial Infections and Mycoses
Germany
14/09/2026
Phase II
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)
2025-524496-23-00Papulopustular Rosacea (PPR)
Novartis Pharma AG
Skin and Connective Tissue Diseases
Bulgaria, France, Italy, Germany
14/09/2026
Phase II
COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…
Unicancer
Neoplasms
France
11/09/2026
Phase IV
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013
2026-526359-75-00Non-Muscle Invasive Bladder Cancer
Urogen Pharma Ltd.
Neoplasms
Estonia, Romania, Spain, Bulgaria, Latvia
11/09/2026
Phase II
Attenuating Calciprotein particles Transformation and Inhibiting Vascular calcification Evolution by Sodium ThioSulphate trial
2026-525680-41-00Vascular Calcification
Radboud universitair medisch centrum Stichting
Therapeutics
Netherlands
11/09/2026
Phase I
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
2025-521143-20-00Bone Morphogenic Protein Receptor type 2 mutation carriers …
Amsterdam UMC Stichting
Diagnosis
Netherlands
10/09/2026
Phase I
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
2026-526282-25-00Systemic lupus erythematosus, sjögren's disease and rheumat…
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Germany
10/09/2026
Phase I
Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone
2025-520498-38-00No therapeutic indication in the current trial with healthy…
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
Physiological processes
Bulgaria
10/09/2026
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00Atopic Dermatitis
Enveda Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Czechia
10/09/2026
Phase III
SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)
2026-526075-35-00Chronic dialysis, Cardiovascular disease
Karolinska University Hospital
Reproductive and Urinary Physiological Phenomena
Sweden
10/09/2026
Rows per page Showing 26–50 of 2500
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.